UNSPSC 51241551: Polyvinyl alcohol/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.

UNSPSC 51241551 Polyvinyl alcohol/sodium chloride is a Commodity code that captures pharmaceutical and over-the-counter (OTC) product supply under state and local cooperative purchasing arrangements. Recent solicitation activity shows state and local governments acquiring generic pharmaceuticals and OTC products through multi-source vendor agreements distributed via authorized wholesalers to participating government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code, procuring pharmaceuticals with specified National Drug Codes (NDC), SKUs, UPCs, and packaging configurations for supply across member state and local facilities. Vendors must meet current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), and carry commercial general liability insurance of $5,000,000 per occurrence. Pricing submissions accept flat-price, net-price (NF30, NF60, NF90), and WAC-minus formats, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing over the contract term, and 5 percent each on administrative fee compliance, EDI capability, and a 3 percent administrative fee commitment.

The code shows activity centered in Minnesota and Oregon through the MMCAP cooperative purchasing vehicle. MMCAP issued a Request for Proposal (S1070000015802) for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with proposals due March 26, 2026 and a February 18, 2026 cutoff for questions. Awards will be announced by May 15, 2026, with resulting agreements effective July 1, 2026 and a two-year initial term for new responders. The contract structure allows sole, dual, or multi-award decisions based on therapeutic considerations, product availability, and member-specific needs, with performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Products must have expiration dates of at least one year from manufacture with a minimum six-month shelf life and full FDA compliance.